As the low response rate [60], adverse effects [61] and drug resistance [62] limit its clinical application, the combination of Sorafenib with other antitumor therapy, such as immunotherapeutic agent R848 [63], PARP inhibitor olaparib [64], and CDK12 inhibitor THZ531 [65], was found to enhance its therapeutic efficiency through reprogramming tumor immune microenvironment, facilitating vascular normalization, and inducing apoptosis or senescence. This evidence concerns the gene CDK12 and neoplasm.